Affordable Access

deepdyve-link
Publisher Website

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Authors
  • Tseng, Alice1
  • Hughes, Christine A2
  • Wu, Janet3
  • Seet, Jason4
  • Phillips, Elizabeth J5, 6
  • 1 1 Toronto General Hospital, Toronto, Canada. , (Canada)
  • 2 2 University of Alberta, Edmonton, AB, Canada. , (Canada)
  • 3 3 Detroit Receiving Hospital, Detroit, MI, USA.
  • 4 4 Sir Charles Gairdner Hospital, Nedlands, WA, Australia. , (Australia)
  • 5 5 Vanderbilt University Medical Center, Nashville, TN, USA.
  • 6 6 Murdoch University, Perth, Western Australia. , (Australia)
Type
Published Article
Journal
Annals of Pharmacotherapy
Publisher
SAGE Publications
Publication Date
Nov 01, 2017
Volume
51
Issue
11
Pages
1008–1022
Identifiers
DOI: 10.1177/1060028017717018
PMID: 28627229
Source
Medline
Keywords
License
Unknown

Abstract

When assessing and managing potential interactions with ritonavir- or cobicistat-based regimens, clinicians need to be aware of important differences and distinctions between these agents. This is especially important for patients with multiple comorbidities and concomitant medications. Additional monitoring or medication dose adjustments may be needed when switching from one booster to another.

Report this publication

Statistics

Seen <100 times